Christian Tucat - 25 Aug 2022 Form 3 Insider Report for Syneos Health, Inc.

Role: Chief Business Officer
Signature: /s/ Sara Epstein, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 25 Aug 2022
Net transactions value: $0
Form type: 3
Filing time: 06 Sep 2022, 17:08:41 UTC
Next filing: 19 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SYNH	Class A Common Stock						17,906	25 Aug 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes (i) 2,890 shares of restricted stock units ("RSUs") that vest on January 15, 2023; (ii) 1,443 RSUs that vest on January 18, 2023; (iii) 468 RSUs that vest on June 15, 2023; (iv) 1,739 RSUs that vest on January 15, 2024; (v) 1,443 RSUs that vest on January 18, 2024; (vi) 468 RSUs that vest on June 15, 2024; (vii) 1,444 RSUs that vest on January 18, 2025; and (viii) 468 RSUs that vest on June 15, 2025, all subject to continued employment.
F2	Includes (i) 305 performance restricted stock units ("PRSUs") that were earned based upon performance criteria for the year ended December 31, 2020 and will vest in full once the Compensation and Management Development Committee (the "Committee") of the Board of Directors of Syneos Health, Inc. determines the attainment level of the performance goals for the year ended December 31, 2022, subject to continued employment; (ii) 582 PRSUs that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2022, subject to continued employment; and (iii) 982 PRSUs that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.

Content

Includes (i) 2,890 shares of restricted stock units ("RSUs") that vest on January 15, 2023; (ii) 1,443 RSUs that vest on January 18, 2023; (iii) 468 RSUs that vest on June 15, 2023; (iv) 1,739 RSUs that vest on January 15, 2024; (v) 1,443 RSUs that vest on January 18, 2024; (vi) 468 RSUs that vest on June 15, 2024; (vii) 1,444 RSUs that vest on January 18, 2025; and (viii) 468 RSUs that vest on June 15, 2025, all subject to continued employment.

Includes (i) 305 performance restricted stock units ("PRSUs") that were earned based upon performance criteria for the year ended December 31, 2020 and will vest in full once the Compensation and Management Development Committee (the "Committee") of the Board of Directors of Syneos Health, Inc. determines the attainment level of the performance goals for the year ended December 31, 2022, subject to continued employment; (ii) 582 PRSUs that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2022, subject to continued employment; and (iii) 982 PRSUs that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.